Definition and epidemiology
Ergotism refers to the clinical syndrome produced by toxic levels of ergot alkaloids, compounds derived from the fungus Claviceps purpurea, which parasitizes rye and other grains, or from pharmaceutical ergot derivatives (ergotamine, dihydroergotamine, methylergonovine, bromocriptine).
Historically, ergotism occurred in epidemics ('St. Anthony's Fire') from eating ergot-contaminated bread, particularly in medieval Europe, and presented with either severe limb gangrene (gangrenous form) or seizures and hallucinations (convulsive form).
Today, ergotism is rare and almost always iatrogenic or drug-related, occurring in patients using ergot alkaloids for migraine prophylaxis or treatment, especially when drug levels rise due to interacting medications or renal/hepatic impairment. It is more common in women (reflecting migraine prevalence) and in patients with underlying vascular disease.
- Ergotism results from ergot alkaloid-induced vasospasm via alpha-adrenergic stimulation
- Classic trigger: ergotamine/dihydroergotamine plus a CYP3A4 inhibitor (macrolide or azole antifungal)
- Presents with cold, cyanotic, painful extremities and diminished pulses
- Angiography may show diffuse, smooth, long-segment arterial narrowing or vasospasm, not focal thrombus
- First step in management is stopping the ergot drug and the interacting agent
- Treat vasospasm with vasodilators: IV nitroprusside/nitroglycerin or calcium channel blockers
- Historical food-borne ergotism from contaminated rye caused epidemics of gangrene or convulsions ('St. Anthony's Fire')
- Untreated severe ergotism can progress to dry gangrene requiring amputation
Etiology and risk factors
- Chronic or excessive use of ergotamine or dihydroergotamine for migraine
- Co-administration of potent CYP3A4 inhibitors: macrolide antibiotics (erythromycin, clarithromycin), azole antifungals (ketoconazole, itraconazole), protease inhibitors (ritonavir)
- Underlying peripheral vascular disease, Raynaud phenomenon, or atherosclerosis
- Renal or hepatic impairment reducing drug clearance
- Heavy smoking (additive vasoconstriction)
- Historical: ingestion of rye bread contaminated with Claviceps purpurea sclerotia
- Concomitant use of other vasoconstrictive migraine drugs (triptans) increases risk
Pathophysiology
Ergot alkaloids act as partial agonists/antagonists at serotonin (5-HT1), alpha-adrenergic, and dopamine receptors, with potent effects on vascular smooth muscle.
The dominant toxic effect is intense, prolonged vasoconstriction of peripheral arteries and arterioles, mediated largely through alpha-adrenergic receptor stimulation. This produces sustained vasospasm that is often refractory to the usual counter-regulatory mechanisms.
Prolonged vasospasm leads to tissue hypoperfusion, ischemia, endothelial injury, and secondary thrombosis, which can progress to irreversible tissue necrosis and gangrene if the vasoconstriction is not reversed. The lower extremities are affected more often than the upper extremities, but any vascular bed (coronary, mesenteric, cerebral) can be involved.
In the convulsive (historical, food-borne) form, ergot alkaloids with central serotonergic/dopaminergic activity (e.g., ergocristine) contribute to seizures, hallucinations, and psychosis rather than predominant vasospasm.
Clinical features
Vascular (gangrenous) form
- Cold, pale, or cyanotic extremities
- Severe limb pain (claudication at rest), paresthesias
- Diminished or absent peripheral pulses
- Progression to blistering, ulceration, and dry gangrene in severe/untreated cases
- Rarely: myocardial, mesenteric, or cerebral ischemia (angina, abdominal pain, stroke-like symptoms)
Convulsive form (historical, ergot-contaminated grain)
- Seizures
- Hallucinations, psychosis
- Muscle twitching, ataxia
General/systemic
- Nausea, vomiting
- Headache
- Hypertension (occasionally hypotension)
Diagnosis
Diagnosis is primarily clinical, based on a history of ergot alkaloid use (often with a precipitating interacting drug) plus signs of peripheral ischemia.
- History: recent or chronic ergotamine/dihydroergotamine use, new macrolide or azole antifungal, renal/hepatic disease
- Physical exam: cold cyanotic limb, weak/absent distal pulses, delayed capillary refill
- Doppler ultrasound or angiography: shows diffuse, smooth, long-segment arterial narrowing or severe vasospasm without a discrete thrombotic occlusion
- Labs: generally nonspecific; obtain renal and hepatic function, creatine kinase if concerned about ischemic muscle injury
- Serum ergot alkaloid levels are not routinely available or clinically useful; diagnosis does not depend on them
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Acute arterial thromboembolism | Sudden onset, discrete occlusion on imaging, embolic source (e.g., atrial fibrillation) |
| Raynaud phenomenon | Episodic, triggered by cold/stress, usually bilateral and symmetric, no fixed ischemia |
| Thromboangiitis obliterans (Buerger disease) | Young smoker, distal extremity ischemia, no large-vessel atherosclerosis |
| Peripheral artery disease (atherosclerotic) | Older patient, risk factors, gradual claudication, discrete stenoses |
| Vasculitis (e.g., polyarteritis nodosa) | Systemic inflammatory markers, multi-organ involvement |
| Cocaine-induced vasospasm | History of stimulant use, similar vasoconstrictive picture |
Management
The cornerstone of treatment is immediate discontinuation of the ergot alkaloid and removal of any interacting precipitant (e.g., stop the macrolide or azole).
Reversing vasospasm
- Vasodilators: intravenous sodium nitroprusside or IV nitroglycerin for severe ischemia; calcium channel blockers (nifedipine, amlodipine) for milder cases
- Supportive measures: keep the limb warm, avoid additional vasoconstrictors (nicotine, caffeine, triptans, beta-blockers)
Adjunctive therapy
- Anticoagulation (heparin) is often used empirically to prevent secondary thrombosis, though evidence is mainly from case series
- Analgesia for ischemic pain
- Consider prostacyclin analogs (e.g., iloprost) in refractory vasospasm, per case reports and some vascular medicine guidelines
Severe/refractory ischemia
- Vascular surgery consultation if ischemia persists despite medical therapy
- Hyperbaric oxygen has been reported anecdotally but is not standard of care
- Amputation may be required for established gangrene
There is no single universally mandated protocol; management follows vascular emergency principles (stop the offending agent, aggressive vasodilation, anticoagulation as needed, surgical referral for non-viable tissue) rather than a disease-specific guideline, since ergotism is now rare.
Complications and prognosis
- Digital or limb gangrene requiring amputation
- Permanent peripheral neuropathy or chronic ischemic pain
- Myocardial infarction, mesenteric ischemia, or stroke from vasospasm in other vascular beds
- Secondary infection of ischemic/necrotic tissue
Prognosis is generally good if the ergot alkaloid is discontinued early and vasospasm is reversed promptly with vasodilator therapy. Delayed recognition significantly increases the risk of irreversible ischemia and limb loss. With modern awareness of drug interactions and more selective migraine therapies (triptans, CGRP antagonists), ergotism has become increasingly rare.
"ERGOT": Erythromycin/azoles (CYP3A4 inhibitors), Raynaud-like vasospasm, Gangrene risk, Occlusion mimics thrombosis on exam, Triptans/other vasoconstrictors worsen it.
Practice questions
1. A 42-year-old woman with migraines has been taking oral ergotamine for several years. She is started on clarithromycin for a sinus infection. Three days later, she develops cold, painful, cyanotic fingers and toes with diminished radial and pedal pulses. Which mechanism best explains her presentation?
2. A patient on dihydroergotamine develops bilateral lower extremity pain, pallor, and absent dorsalis pedis pulses. Angiography shows smooth, diffuse narrowing of multiple arterial segments without a discrete filling defect. What is the most appropriate immediate management step?
3. A medieval historical account describes a village epidemic involving some residents with painful black, gangrenous limbs and others with seizures and hallucinations after consuming bread made from a local grain harvest. What is the most likely cause?
Frequently asked questions
What causes ergotism?
Ergotism is caused by toxic levels of ergot alkaloids, most often from ergotamine or dihydroergotamine used for migraine, especially when combined with drugs that inhibit CYP3A4 metabolism such as macrolide antibiotics or azole antifungals. Historically, it was caused by eating rye bread contaminated with the fungus Claviceps purpurea. Both routes raise ergot alkaloid levels enough to cause severe vasoconstriction.
What are the first symptoms of ergotism?
The earliest symptoms are usually coldness, numbness, or tingling in the fingers or toes, followed by pain and a pale or bluish discoloration of the affected extremity. Nausea and headache may also occur. As vasospasm persists, pulses weaken and the skin can progress to blistering or ulceration if untreated.
How is ergotism diagnosed?
Ergotism is diagnosed clinically based on a history of ergot alkaloid use, often with a recently added interacting drug, plus physical signs of limb ischemia such as coldness, cyanosis, and weak pulses. Doppler ultrasound or angiography can confirm diffuse, smooth arterial narrowing or vasospasm without a discrete clot. Blood ergot levels are not routinely used for diagnosis.
Is ergotism curable?
Yes, ergotism is reversible in most cases if recognized early and the causative ergot alkaloid is stopped promptly, combined with vasodilator therapy. Delayed treatment, however, can lead to irreversible tissue ischemia and gangrene requiring amputation. Overall prognosis depends heavily on how quickly the vasospasm is reversed.
Ergotism vs Raynaud phenomenon — what is the difference?
Ergotism is caused by a specific drug or toxin and produces persistent, often severe vasospasm that can progress to fixed ischemia and gangrene without treatment. Raynaud phenomenon is typically episodic, triggered by cold or stress, and resolves between attacks without permanent tissue damage. A history of ergot alkaloid exposure points to ergotism, while recurrent cold-triggered color changes suggest Raynaud phenomenon.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: T62.2
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.